CVS Health Corp vs Kinross Gold Corporation — how do they compare? CVS Health Corp trades at $86.24 (market cap $112.29B), while Kinross Gold Corporation trades at $23.7 (market cap $27.62B). The key difference: CVS Health Corp is far larger — about 4.1× Kinross Gold Corporation's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Kinross Gold Corporation for 53 Days on average.
| CVS | KGC | |
|---|---|---|
Market Cap | $112.29B | $27.62B |
Volume | 7,763,676 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $110.60 | $38.06 |
52-Week Low | $70.08 | $22.47 |
Typical Hold Time | 83 Days | 53 Days |
Enterprise Value | $174.64B | $25.70B |
Dividend Yield | 3.03% | 0.69% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $86.16, down 2.04% for the day, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst consensus is overwhelmingly positive, with 35 of 41 analysts rating the stock a Buy and a consensus price target of $111.20, implying significant upside. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
The outlook for CVS remains favorable based on fundamental strength and analyst optimism, but risks include reimbursement pressure, regulatory scrutiny, and a high debt load. The stock's current valuation metrics, such as a P/E of 23.17 and P/S of 0.27, appear reasonable relative to historical levels, supporting a constructive view for long-term investors despite near-term technical weakness.
Kinross Gold (KGC) trades at $23.74, up 2.42% with strong fundamentals including 37.52% net margin and 36.95% ROE. The stock shows bearish technical signals despite recent earnings beats and analyst consensus of $38.80 price target. Recent news highlights production guidance cuts and increased shareholder returns, creating mixed sentiment.
KGC offers attractive valuation with 8.87 P/E but faces near-term headwinds from production issues. The company maintains strong cash flow growth and balance sheet strength, though legal investigations and operational challenges present risks. Wall Street maintains bullish long-term outlook with 59% buy ratings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →